Category Archives: Business of Biotech

Plexxikon Announces PLX4032 Phase I Clinical Trial Results

Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients. PLX4032 targets the BRAFV600E mutation that occurs in about 50 percent of melanomas and about eight percent of solid tumors. Tumor shrinkage has been observed in nearly all of the currently evaluable patients in the extension study, reflecting a 70 percent response rate. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and Naval Medical Research Center for the development of Dengue vaccines and point-of-care diagnostics. The goal of the R&D project is to evaluate the company’s Directed Expansion of Epitope Permutations (DEEP) technology to potentially design DENV-specific peptide copolymers. The results of this effort have the potential to provide insights into dengue immunity and advance the development of a protective vaccine.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Idera Pharmaceuticals Phase 2 Results for Renal Cell Carcinoma Therapy

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, a monotherapy in patients with Renal Cell Carcinoma. Progression-free survival medians for treatment-naïve patients were 4.5 months at 0.16 mg/kg/week and 1.9 months at 0.64 mg/kg/week.  The most common adverse events included fatigue, nausea, chills, headache, and pyrexia.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Cleveland BioLabs Receives Additional Funding for Radiation Project

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an additional $2.3 million in funding for a $13.3 million contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) for the development of Radiation Countermeasure Protectan CBLB502. In addition, BARDA increased the first milestone-based option from $4.0 million to $6.3 million, increasing the total contract value including all milestone-based options from $13.3 million to $15.6 million over the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags:

Dendreon’s PROVENGE making regulatory and commercialization progress

Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s investigational prostate cancer product. Dendreon expects to prepare for commercialization of PROVENGE by the middle of next year. Dendreon further plans to initiate a clinical trial of NEUVENGE™ (lapuleucel-T) to treat bladder cancer, and potentially, breast and colorectal cancers. At today’s analyst event, the company also reported the expansion of its manufacturing facility in New Jersey and the addition of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,